MARKET

KDNY

KDNY

Chinook Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.12
-0.29
-2.34%
Opening 14:40 09/20 EDT
OPEN
12.26
PREV CLOSE
12.41
HIGH
12.64
LOW
12.09
VOLUME
186.44K
TURNOVER
--
52 WEEK HIGH
21.68
52 WEEK LOW
10.95
MARKET CAP
542.97M
P/E (TTM)
-1.8487
1D
5D
1M
3M
1Y
5Y
Chinook Therapeutics to Present at Upcoming Investor Conferences
Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in fireside c...
GlobeNewswire · 6h ago
'Insiders Go Big on These 3 Hot Stocks' -TipRanks
https://www.tipranks.com/news/article/insiders-go-big-on-these-3-hot-stocks/
Benzinga · 08/25 15:41
Baker Bros. Advisors Lp Buys Verve Therapeutics Inc, Nurix Therapeutics Inc, Legend Biotech ...
GuruFocus News · 08/24 18:38
Chinook Therapeutics director buys 208,500 shares
On August 18, Chinook Therapeutics (NASDAQ:KDNY) Director, Srinivas Akkaraju bought 208,500 shares of the company at price of $11.58. This brings his total share holding to ~3.38M shares. The stock
Seekingalpha · 08/23 20:13
Silverarc Capital Management, Llc Buys Chinook Therapeutics Inc, Amryt Pharma PLC, Mirati ...
GuruFocus News · 08/23 06:28
Chinook Therapeutics Inc (KDNY) President, CEO Eric Dobmeier Bought $118,200 of Shares
GuruFocus News · 08/20 16:15
Insider Trends: 90-Day Buying Trend Extended with Insider Purchase of Chinook Therapeutics Stock
MT Newswires · 08/19 18:06
Frazier Management Llc Buys Iovance Biotherapeutics Inc, Chinook Therapeutics Inc, Autolus ...
GuruFocus News · 08/13 18:38
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of KDNY. Analyze the recent business situations of Chinook Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average KDNY stock price target is 32.71 with a high estimate of 40.00 and a low estimate of 25.00.
EPS
Institutional Holdings
Institutions: 151
Institutional Holdings: 31.83M
% Owned: 71.05%
Shares Outstanding: 44.80M
TypeInstitutionsShares
Increased
36
4.45M
New
23
4.14M
Decreased
14
1.31M
Sold Out
11
411.75K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.06%
Pharmaceuticals & Medical Research
-1.70%
Key Executives
Chairman/President/Chief Executive Officer/Director
Eric Dobmeier
Chief Financial Officer
Eric Bjerkholt
Chief Operating Officer
Tom Frohlich
Chief Scientific Officer
Andrew King
Other
Alan Glicklich
Lead Director/Independent Director
Jerel Davis
Independent Director
Srinivas Akkaraju
Independent Director
William Greenman
Independent Director
Michelle Griffin
Independent Director
Ross Haghighat
Independent Director
Dolca Thomas
No Data
About KDNY
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing precision medicines for kidney diseases. The Company's development programs consist of Atrasentan, BION-1301 and CHK-336. Atrasentan is a potent and selective endothelin A receptor antagonist that are developed for the treatment of proteinuric glomerular diseases. BION-1301 is an investigational humanized IgG4 monoclonal antibody that blocks APRIL binding to both the B-cell maturation antigen (BCMA), and transmembrane activator and CAML interactor (TACI), receptors, as a disease-modifying therapy for Immunoglobulin A Nephropathy (IgAN). CHK-336 is a liver-targeted oral small molecule lactate dehydrogenase (LDHA), inhibitor, which are developed for the treatment of primary hyperoxaluria.

Webull offers kinds of Chinook Therapeutics Inc stock information, including NASDAQ:KDNY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KDNY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KDNY stock methods without spending real money on the virtual paper trading platform.